How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

- Tiong, Ing Soo, Wall, Meaghan, Marlton, Paula, Johnston, Amanda, Enjeti, Anoop, Fong, Chun Yew, Cull, Gavin, Larsen, Stephen, Kennedy, Glen, Schwarer, Anthony, Kipp, David, Ramanathan, Sundra, Bajel, Ashish, Verner, Emma, Tiley, Campbell, Morris, E, Hahn, U, Moore, J, Taper, J, Purtill, D, Warburton, P, Stevenson, W, Murphy, N, Kalro, Akash, Tan, P, Beligaswatte, A, Mutsando, H, Hertzberg, M, Shortt, J, Szabo, F, Dunne, K, Wei, AH, Australasian Leukaemia and Lymphoma Group (ALLG),, Fleming, Shaun, Roberts, Andrew W., Thiagarajah, Nisha, Chua, Chong Chyn, Latimer, Maya, Yeung, David

TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate

- Hernández-Mitre, María Patricia, Morpeth, Susan C., Roberts, Jason A., Venkatesh, Balasubramanian, Hills, Thomas E., Davis, Joshua, Mahar, Robert K., McPhee, Grace, Jones, Mark, Totterdell, James, Tong, Steven Y. C.

A Global Core Outcome Measurement Set for Snakebite Clinical Trials

- Abouyannis, Michael, Esmail, Hanif, Alcoba, Gabriel, Cammack, Nick, Chippaux, Jean-Philippe, Coldiron, Matthew E., Gutiérrez, José M., Habib, Abdulrazaq G., Harrison, Robert A., Isbister, Geoffrey K., Lavonas, Eric J., Martins, Diogo, Hamaluba, Mainga, Ribeiro, Isabela, Watson, JA, Williams, DJ, Casewell, NR, Walker, SA, Lalloo, DG, Snakebite Global Core Outcome Set Study Group,, Ngama, Mwanajuma, Mwangudzah, Hope, Mumba, Noni, Yeri, Betty K., Mwalukore, Salim, Alphan, Hassan J., Aggarwal, Dinesh

An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials

- Schilling, Chris, Tew, Michelle, Bunzli, Samantha, Shadbolt, Cade, Lohmander, L. Stefan, Balogh, Zsolt J., Paolucci, Francesco, Choong, Peter F., Dowsey, Michelle M., Clarke, Philip

Disability accrual in primary and secondary progressive multiple sclerosis

- Harding-Forrester, Sam, Roos, Izanne, Horakova, Dana, Kubala Havrdova, Eva, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'Maison, Francois, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ozakbas, Serkan, Nguyen, Ai-Lan, Amato, Maria Pia, Gerlach, O, Sola, P, Ferraro, D, Buzzard, K, Skibina, O, Lechner-Scott, Jeannette, Alroughani, R, Boz, C, Van Pesch, V, Malpas, Charles B., Cartechini, E, Terzi, M, Maimone, D, Ramo-Tello, C, Yamout, B, Khoury, SJ, La Spitaleri, D, Sa, MJ, Blanco, Y, Granella, F, Diouf, Ibrahima, Slee, M, Butler, E, Sidhom, Y, Gouider, R, Bergamaschi, R, Karabudak, R, Ampapa, R, Sanchez-Menoyo, JL, Prevost, J, Castillo-Trivino, T, Moradi, Nahid, McCombe, PA, Macdonell, R, Laureys, G, Van Hijfte, L, Oh, J, Altintas, A, de Gans, K, Turkoglu, R, van der Walt, A, Butzkueven, H, Sharmin, Sifat, Vucic, S, Barnett, M, Cristiano, E, Hodgkinson, S, Iuliano, G, Kappos, L, Kuhle, J, Shaygannejad, V, Soysal, A, Weinstock-Guttman, B, Izquierdo, Guillermo, Van Wijmeersch, B, Kalincik, T, Eichau, Sara, Patti, Francesco

Is it ethical to use teriflunomide as an active comparator in phase 3 trials?

- Giovannoni, Gavin, Hawkes, Christopher H., Lechner-Scott, Jeannette, Levy, Michael, Yeh, E. Ann

Prioritizing clinical trial quality assurance for photons and protons: A failure modes and effects analysis (FMEA) comparison

- Taylor, Paige A., Miles, Elizabeth, Corning, Coreen, Effeney, Rachel, Healy, Brendan, Moore, Alisha, Nakamura, Mitsuhiro, Patel, Samir, Shaw, Maddison, Stock, Markus, Lehmann, Joerg, Clark, Catharine H., Hoffmann, Lone, Kelly, Sarah M., Kry, Stephen F., Møller, Ditte Sloth, Palmans, Hugo, Akbarov, Kamal, Aznar, Marianne C., Clementel, Enrico

Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans

- Naismith, Sharon L., Michaelian, Johannes C., Breakspear, Michael, Ahern, Susannah, Fripp, Jurgen, Schofield, Peter R., Sachdev, Perminder S., Rowe, Christopher C., Santos, Cherry, Mehrani, Inga, Robertson, Joanne, Wallis, Kasey, Lin, Xiaoping, Ward, Stephanie A., Martins, Ralph, Masters, Colin L.

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

- Foster, Jessica B., Alonso, Marta M., Sayour, Elias, Davidson, Tom B., Persson, Mika L., Dun, Matthew D., Kline, Cassie, Mueller, Sabine, Vitanza, Nicholas A., van der Lugt, Jasper

Unlocking the DOOR-how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials

- Ong, Sean W. X., Petersiel, Neta, Loewenthal, Mark R., Daneman, Nick, Tong, Steven Y.C., Davis, Joshua S.

SEAFARER – A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice: SEAFARER - sensitivity of patient specific quality assurance, PSQA

- Lehmann, Joerg, Hussein, Mohammad, Claridge Mackonis, Elizabeth, Meehan, Carole, Patel, Rushil, Ray, Xenia, Shaw, Maddison, Shepherd, Justin, Smyth, Gregory, Standen, Therese S., Subramanian, Brindha, Greer, Peter B., Barry, Miriam A., Clark, Catharine H., Siva, Shankar, Moore, Alisha, Chu, Michael, Díez, Patricia, Eaton, David J., Harwood, Jeffrey, Lonski, Peta

T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma

- Niessen, Natalie M., Fricker, Michael, McDonald, Vanessa M., Gibson, Peter G.

The benefits of data sharing and ensuring open sources of systematic review data

- Yoong, Sze Lin, Turon, Heidi, Grady, Alice, Hodder, Rebecca, Wolfenden, Luke

Exacerbations of COPD

- Man, William D-C., Jones, Arwel W.

How to include patient-reported outcome measures in clinical trials

- McGee, Richard G.

Current update on preclinical and clinical studies of resveratrol, a naturally occurring phenolic compound

- Samuel, Vijaya Paul, Gupta, Gaurav, Dahiya, Rajiv, Jain, Dev Anand, Mishra, Anurag, Dua, Kamal

EPID-based dosimetry for remote auditing of radiotherapy clinical trials

- Miri, Narges

Participant-centered online active surveillance for adverse events following vaccination in a large clinical trial: feasibility and usability study

- Munnoch, Sally-Anne, Cashman, Patrick, Peel, Roseanne, Attia, John, Hure, Alexis, Durrheim, David N.

Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials

- Manton, Kerry J., Gauld, Cassandra S., White, Katherine M., Griffin, Paul M., Elliott, Suzanne L.

Long-term disability trajectories in primary progressive MS patients: a latent class growth analysis

- Signori, Alessio, Izquierdo, Guillermo, Duquette, Pierre, Boz, Cavit, Grammond, Pierre, Terzi, Murat, Singhal, Bhim, Alroughani, Raed, Petersen, Thor, Ramo, Cristina, Oreja-Guevara, Celia, Spitaleri, Daniele, Lugaresi, Alessandra, Lechner-Scott, Jeanette, Hupperts, Raymond, Grand'Maison, Francois, Sola, Patrizia, Horakova, Dana, Havrdova, Eva, Prat, Alexandre, Girard, Marc